Revenue and Biogen Essay examples

Submitted By sunmyang
Words: 5823
Pages: 24
Open Document
Company profile
Biogen Idec Inc. (BIIB) is an US-based company that concerns itself with the discovery, development and manufacturing of therapies for the treatment of several diseases such as hemophilia, autoimmune disorders, multiple sclerosis and neurodegenerative diseases. The company was founded in 1985 and its headquarters are located in Cambridge Massachusetts. Biogen Idec Inc. was formerly known as IDEC Pharmaceuticals Corporation before changing its name in November 2003.
Biogen finds itself in the Biotechnology industry, which is the second largest industry in the Healthcare sector, a sector that has a market capitalization of over 60 trillion dollars and an average ROE of 18.42%. The Biotechnology industry shares its participation with many other important industries in this sector such as: drug manufacturers, medical appliances & equipment, health care plans, etc.
This Cambridge-based company is the leader in multiple sclerosis (MS) research and has developed a series of very effective treatments for this disease. Biogen Idec has an extremely high concentration on research and development and it’s committed to environmental sustainability, being ranked second in the Global 100 Index.
Industry Analysis
Industry at a glance
The Biotechnology Industry uses living organisms and cellular techniques to provide chemicals, food and services (in the form of treatments) that meet human needs. The primary activities of this industry are: cell tissue culture engineering, protein sequencing, synthesis and engineering, and DNA coding, mapping and sequencing. On the other hand, the services and products provided by this industry range from agriculture and aquaculture technologies to animal and human health technologies; the last take up 57% of the total composition of the industry (see Exhibit 1).
The Biotechnology industry has over 1,900 businesses, which add up to a total of $98.5 billion in revenues and $5.7 billion in profit; this means that companies have an average profit margin of 5.79%. When it comes to market share, the industry has four major players that make up for more than half of the industry’s capitalization: Gilead Sciences, Amgen Inc., Genentech and Monsanto (see Exhibit 2).
Structure
The Biotechnology industry is relatively young and rapidly growing industry with very promising growth prospects in the next 5 years. The peculiarity of this industry is that it has a very wide range of product applications and target markets and also a large number of disparate firms. Due to the industry’s highly diverse nature, revenue growth is influenced by many factors. The key external drivers influencing industry performance are: investor uncertainty, R&D expenditures, prices of agricultural commodities and medical needs from the general population.
Investor uncertainty is tremendously important for this industry because of its high reliance on large capital investments to function. As investor uncertainty grows, access to investments narrows. During 2014 investor uncertainty has decreased, posing a great opportunity for the industry.
Other determinant factors which influence performance are R&D expenditures and technology. Biotechnology is one of the most active industries when it comes to research and development. Investment in R&D is key for the development for drugs, vaccines, disease resistant crops, enzymatic manufacturing processes, etc.
The demand and price of corn influences agricultural activity and increases the demand for agricultural technologies provided by this industry. Since the amount of available land for harvest is decreasing, more efficient technologies are required to produce food products and fuel from corn; here’s is where biotechnology firms come in. Finally, more than 50.0% of the industry’s revenues come from the sale of healthcare products. Factors such as: aging of the population, life expectancy and increase of medical needs and treatments drives up the
Show More

Related Documents: Revenue and Biogen Essay examples

Stock Market and Genentech Essay

Roche the right to sell Genentech on non US markets, but only till 2015. After that the company faces a high risk of losing the right. Genentech’s cancer drug, Avastin, may not be successfully tested and may be banned from sale. This risk of loss of revenue will also have to be borne by the company. New competitors may come with competing best selling drugs, which will again lead to a risk of reduction in growth prospects. 2. As a majority shareholder of Genentech, what responsibilities does Roche…

Words 1683 - Pages 7

Biodel Inc Essays

genetic engineering field. The company has basic but not wide experience if this field but they have been a major supplier of molecular biology products. At the moment, there are four major competitors in the market; Cetus, Genentech, Genex and Biogen. The basic purpose of this field is to engineer a cell to produce a specific biological product. Competitors use the bacterium E. coli as their host cell, for the most part. Biodel has the opportunity to enter the market with a new strategy…

Words 1904 - Pages 8

Today's Pharmaceutical Supply Chain

States and four in Europe. It is predicted that North and South America, Europe and Japan will continue to account for a full 85% of the global pharmaceuticals market well into the 21st century. Companies currently spend one-third of all sales revenue on marketing their products - roughly twice what they spend on research and development. In the US there are many pharmaceutical companies. Many of these manufacture their own products while others outsource the production of its medicine. In…

Words 4216 - Pages 17

Essay on Syllabus: Management and Outline Form Response

– more than 90% of the businesses in the US employ less than 20 people; only about 1% of the more than 6 million US companies have more than 500 employees; and only 4% of the 21 million US enterprises that filed tax returns in 1992 reported gross revenues greater than $1 million. Obviously, there is a lot more to entrepreneurship than just starting a company. This course is about how to build an entrepreneurial company – the challenges and hurdles that must be overcome in order to make the transition…

Words 4509 - Pages 19

Fundamental Analysis and Aswath Damodaran Essay

Valuation Aswath Damodaran www.damodaran.com Aswath Damodaran 1 Some Initial Thoughts " One hundred thousand lemmings cannot be wrong" Graffiti Aswath Damodaran 2 Misconceptions about Valuation  Myth 1: A valuation is an objective search for “true” value • •  Myth 2.: A good valuation provides a precise estimate of value • •  Truth 1.1: All valuations are biased. The only questions are how much and in which direction. Truth 1.2: The direction and magnitude of the bias in your valuation…

Words 9402 - Pages 38

Alliance Management At Eli Lilly Lesson Essay

Alliance Management at Eli Lilly: Lessons on How Alliance Capability Contributes to Sustainable Advantage Luvison, Dave, Journal of Applied Management and Entrepreneurship Executive Summary Alliances have long been an important strategy in the pharmaceutical industry even thoughmore than half fail. Eli Lilly set out to create a core competence in the area of strategic alliancemanagement that would not only improve its success rate, but also differentiate the firm fromits competitors in the industry…

Words 8918 - Pages 36

Jack: Case Study and Emerging Enterprise Essay

professional investment, and of those that are funded, only 15-20% ever generate any serious returns. On the other hand, there are a lot of small businesses out there – in 2008, only 12% of 29 million US businesses reported more than $2.5 million in revenues; more than 95% were sole proprietorships, and more than 98% employed fewer than 20 people. Of the 5.9 million firms with employees, only 0.4% had more than 500 employees. Obviously, there is a lot more to entrepreneurship than just starting a company…

Words 8292 - Pages 34